open access

Vol 7, No 2 (2004)
Published online: 2004-06-02
Submitted: 2012-01-23
Get Citation

Marked survival prolongation of mice bearing a transplantable colon adenocarcinoma by treatment with radioactive platinum-[125I]histamine complex. Preliminary report

Piotr Garnuszek
Nucl. Med. Rev 2004;7(2):113-116.

open access

Vol 7, No 2 (2004)
Published online: 2004-06-02
Submitted: 2012-01-23

Abstract

BACKGROUND: Recently, a new PtCl2-histamine complex, and its radioactive analogues labelled with I-131 and I-125 have been synthesised and investigated both in vitro and in vivo. In this preliminary report the survival rate of radioactive platinum-[125I] histamine therapy in tumour-bearing mice is demonstrated.
MATERIAL AND METHODS: A murine model of transplantable colon adenocarcinoma (C38) in C57BL/6 mice (15 days postimplantation) was used for the experiment. Three groups of animals were treated every 2–3 days with five intraperitoneal injections of the following preparations: PtCl2Hist (total dose of Pt - 125 μmol/kg), PtCl2[125I]Hist (total dose of I-125 - 4.2 MBq; Pt - 13 μmol/kg), and Active/Cold” - PtCl2[125I]Hist/PtCl2Hist (I-125 - 4.2 MBq; Pt - 125 μmol/kg). A solution of 15% dimethylformamide in saline was applied to the control group. A survival analysis with the Kaplan-Meier estimation of survival curves and a statistical comparison by a log-rank test was applied to evaluate the anticancer activity of the tested preparations.
RESULTS: Treatment of the animals with platinum-histamine preparations resulted in a significant prolongation of survivals, especially if the radioactive complex with carrier-added PtCl2Hist (p < 0.005) was applied. The highest, almost a 60% prolongation of survival was observed in the Active/Cold group (MStr/MScon ratio = 1.58, 95% CI 1.22-1.93). For this group there was the lowest risk of death (hazard ratio HR = 0.29), whereas HR = 0.45 and 0.47 were found in the animals treated with unattended PtCl2Hist and 125I-labelled complex, respectively.
CONCLUSION: The significant enhancement of in vivo anti-cancer activity by a concomitant combination of the therapeutic factors, i.e. cytotoxic/cytostatic activity of the platinum(II)-histamine and the Auger electrons effects generated by the attached I-125 radionuclide, was found on the murine model of transplantable colon adenocarcinoma.

Abstract

BACKGROUND: Recently, a new PtCl2-histamine complex, and its radioactive analogues labelled with I-131 and I-125 have been synthesised and investigated both in vitro and in vivo. In this preliminary report the survival rate of radioactive platinum-[125I] histamine therapy in tumour-bearing mice is demonstrated.
MATERIAL AND METHODS: A murine model of transplantable colon adenocarcinoma (C38) in C57BL/6 mice (15 days postimplantation) was used for the experiment. Three groups of animals were treated every 2–3 days with five intraperitoneal injections of the following preparations: PtCl2Hist (total dose of Pt - 125 μmol/kg), PtCl2[125I]Hist (total dose of I-125 - 4.2 MBq; Pt - 13 μmol/kg), and Active/Cold” - PtCl2[125I]Hist/PtCl2Hist (I-125 - 4.2 MBq; Pt - 125 μmol/kg). A solution of 15% dimethylformamide in saline was applied to the control group. A survival analysis with the Kaplan-Meier estimation of survival curves and a statistical comparison by a log-rank test was applied to evaluate the anticancer activity of the tested preparations.
RESULTS: Treatment of the animals with platinum-histamine preparations resulted in a significant prolongation of survivals, especially if the radioactive complex with carrier-added PtCl2Hist (p < 0.005) was applied. The highest, almost a 60% prolongation of survival was observed in the Active/Cold group (MStr/MScon ratio = 1.58, 95% CI 1.22-1.93). For this group there was the lowest risk of death (hazard ratio HR = 0.29), whereas HR = 0.45 and 0.47 were found in the animals treated with unattended PtCl2Hist and 125I-labelled complex, respectively.
CONCLUSION: The significant enhancement of in vivo anti-cancer activity by a concomitant combination of the therapeutic factors, i.e. cytotoxic/cytostatic activity of the platinum(II)-histamine and the Auger electrons effects generated by the attached I-125 radionuclide, was found on the murine model of transplantable colon adenocarcinoma.
Get Citation

Keywords

Pt(II)Cl 2-histamine complex; iodine-125; transplantable colon adenocarcinoma (C38); tumour-bearing C57BL/6/C38 mice; survival analysis

About this article
Title

Marked survival prolongation of mice bearing a transplantable colon adenocarcinoma by treatment with radioactive platinum-[125I]histamine complex. Preliminary report

Journal

Nuclear Medicine Review

Issue

Vol 7, No 2 (2004)

Pages

113-116

Published online

2004-06-02

Bibliographic record

Nucl. Med. Rev 2004;7(2):113-116.

Keywords

Pt(II)Cl 2-histamine complex
iodine-125
transplantable colon adenocarcinoma (C38)
tumour-bearing C57BL/6/C38 mice
survival analysis

Authors

Piotr Garnuszek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl